Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
2.
Transpl Immunol ; 69: 101449, 2021 12.
Artigo em Inglês | MEDLINE | ID: mdl-34391884

RESUMO

BACKGROUND: Patients awaiting kidney transplantation are regularly screened for HLA-antibodies, but there is scarce data about the optimal interval. METHODS: Results from Complement-dependent cytotoxicity testing (CDC) for waitlisted patients were reviewed for increases in panel reactive antibodies (PRA) by at least 10%-points. Clinical records were screened for historic immunizing events and possible trigger factors preceding the PRA-increase. Additionally, non-pretransplanted men tested negative for HLA antibodies by solid-phase assays (SPA) out of their first two samples on the waiting list ("non-immunized men") were evaluated for detection of HLA antibodies by SPA during their further stay on the waiting list. RESULTS: 15,360 samples from 1928 patients tested by CDC were analyzed for changes in PRA. PRA-increases occurred most frequently in patients waitlisted recently for retransplantation (annual incidence 6%). Removal of previous transplants, severe infections and/or reduced immunosuppression triggered 65% of PRA-increases during the first year after waitlisting. Transfusions accounted for 55% of PRA-increases in later years. Leucocyte-reduced red blood cell units not only boosted historic antibodies, but even induced primary immunization. In the second part of the study, 6780 samples tested by SPA from 703 non-immunized men were evaluated for development of HLA-antibodies. Only 9 men (1.3%) turned HLA antibody-positive (annual incidence 0.4%). CONCLUSION: A uniform screening interval does not fit all: Frequencies should be highest in patients newly waitlisted for re-transplant and lowest in non-immunized men. Transfused patients should be monitored closely for development of HLA-antibodies even if leukoreduced products are used.


Assuntos
Transplante de Rim , Antígenos HLA , Teste de Histocompatibilidade , Humanos , Terapia de Imunossupressão , Isoanticorpos , Masculino , Listas de Espera
3.
Dtsch Med Wochenschr ; 144(20): 1449-1454, 2019 10.
Artigo em Alemão | MEDLINE | ID: mdl-31594022

RESUMO

HISTORY AND CLINICAL FINDINGS: We report the case of a 30 years old man presenting with cough and a sore throat. The physical examination showed a painful neck, a scleral icterus, inflammation of the posterior pharyngeal wall and tonsils. INVESTIGATIONS: Initial laboratory studies revealed an increase in white blood cells, a pronounced reduction of platelets, an elevated CRP and renal failure. Ultrasound examination of his neck showed a thrombosis of the jugular vein. Blood cultures were drawn and led to the identification of fusobacterium necrophorum. DIAGNOSIS: Lemierre's Syndrom accompanied by purulent abscess-forming thrombophlebitis of the right external jugular vein. TREATMENT AND COURSE: Antibiotic therapy was started with ceftazidime plus levofloxacin and was adjusted to ampicillin plus clindamycin. As resistance to ampicillin was detected, therapy was readjusted to meropenem. Inflammation, renal parameters, transaminases and bilirubin decreased. The patient improved clinically and was discharged after 19 days in hospital. CONCLUSION: The Lemierre's Syndrome is a rare and often underdiagnosed septic disease followed on pharyngeal infections leading to purulent thromboplebitis of small veins. An appropriate antibiotic therapy is mandatory for a successful treatment of this disease.


Assuntos
Síndrome de Lemierre , Adulto , Antibacterianos/uso terapêutico , Fusobacterium necrophorum , Humanos , Veias Jugulares/diagnóstico por imagem , Veias Jugulares/patologia , Masculino , Faringite/microbiologia , Tromboflebite/microbiologia
4.
Nephrol Dial Transplant ; 31(1): 95-103, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26180049

RESUMO

BACKGROUND: Shiga toxin-producing, enteroaggregative Escherichia coli was responsible for the 2011 outbreak of haemolytic uraemic syndrome (HUS). The present single-centre, observational study describes the 1-year course of the disease with an emphasis on kidney function. Outcome data after 1 year are associated with treatment and patient characteristics at onset of HUS. METHODS: Patients were treated according to a standardized approach of supportive care, including a limited number of plasmapheresis. On top of this treatment, patients with severe HUS (n = 35) received eculizumab, a humanized anti-C5 monoclonal antibody inhibiting terminal complement activation. The per-protocol decision--to start or omit an extended therapy with eculizumab accompanied by azithromycin--separated the patients into two groups and marked Day 0 of the prospective study. Standardized visits assessed the patients' well-being, kidney function, neurological symptoms, haematological changes and blood pressure. RESULTS: Fifty-six patients were regularly seen during the follow-up. All patients had survived without end-stage renal disease. Young(er) age alleviated restoring kidney function after acute kidney injury even in severe HUS. After 1 year, kidney function was affected with proteinuria [26.7%; 95% confidence interval (CI) 13.8-39.6], increased serum creatinine (4.4%, CI 0.0-10.4), increased cystatin C (46.7%, CI 32.1-61.3) and reduced (<90 mL/min) estimated glomerular filtration rate (46.7%, CI 32.1-61.3). Nine of the 36 patients without previous hypertension developed de novo hypertension (25%, CI 10.9-39.1). All these patients had severe HUS. CONCLUSIONS: Although shiga toxin-producing Escherichia coli (STEC)-HUS induced by O104:H4 was a life-threatening acute disease, follow-up showed a good recovery of organ function in all patients. Whereas kidney function recovered even after longer duration of dialysis, chronic hypertension developed after severe HUS with neurological symptoms and could not be prevented by the extended therapy.


Assuntos
Escherichia coli Êntero-Hemorrágica , Infecções por Escherichia coli/complicações , Síndrome Hemolítico-Urêmica/complicações , Hipertensão/microbiologia , Insuficiência Renal Crônica/microbiologia , Adulto , Antibacterianos/uso terapêutico , Anticorpos Monoclonais Humanizados/uso terapêutico , Azitromicina/uso terapêutico , Inativadores do Complemento/uso terapêutico , Quimioterapia Combinada , Infecções por Escherichia coli/tratamento farmacológico , Infecções por Escherichia coli/microbiologia , Feminino , Seguimentos , Taxa de Filtração Glomerular , Síndrome Hemolítico-Urêmica/tratamento farmacológico , Síndrome Hemolítico-Urêmica/microbiologia , Humanos , Hipertensão/prevenção & controle , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Insuficiência Renal Crônica/prevenção & controle , Resultado do Tratamento
5.
Am J Physiol Regul Integr Comp Physiol ; 309(11): R1406-14, 2015 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-26400183

RESUMO

ANG II interacts with the sympathetic nervous system at central nervous blood pressure-regulating structures, including the baroreflex. It is unknown whether prolonged BP elevation mediated by high ANG II plasma levels could induce a persistent shift of the central nervous baroreflex setpoint, lasting beyond the short ANG II plasmatic half time of a few seconds, thereby consolidating elevated BP and/or increased SNA in healthy humans. In a blinded crossover design, ANG II or placebo (saline) was infused for a 6-h period in 12 resting normotensive students (6 males, 6 females) raising BP to borderline hypertensive levels. Between 60 and 120 min after the infusion period, muscle sympathetic nerve activity (MSNA) was assessed microneurographically and correlated with oscillometric BP measurements and heart rate at supine rest (baseline) and during pharmacologic baroreceptor challenge. Infusion of ANG II increased BP to borderline-hypertensive levels, as intended, whereas heart rate remained unaltered. At baroreflex assessment (i.e., 60-120 min after end of infusion period), systolic BP was significantly higher compared with placebo (Δ8.4 ± 3.1 mmHg; P < 0.05), whereas diastolic values were nearly equal between conditions. Baseline MSNA was neither decreased nor increased, and baroreflex sensitivity to vasoactive drug challenge was not altered. Our results show that elevation of ANG II plasma levels over 6 h was able to increase systolic, but not diastolic, BP far beyond blood-mediated ANG II effects. MSNA or heart rate did not counter-regulate this BP elevation, indicating that ANG II had sustainably reset the central nervous BP threshold of sympathetic baroreflex function to accept elevated BP input signals without counter-regulatory response.


Assuntos
Angiotensina II/administração & dosagem , Barorreflexo/efeitos dos fármacos , Pressão Sanguínea/efeitos dos fármacos , Vasoconstritores/administração & dosagem , Adaptação Fisiológica , Angiotensina II/sangue , Estudos Cross-Over , Feminino , Voluntários Saudáveis , Frequência Cardíaca , Humanos , Infusões Parenterais , Masculino , Músculo Esquelético/inervação , Método Simples-Cego , Fatores de Tempo , Rigidez Vascular , Vasoconstritores/sangue , Adulto Jovem
6.
Hypertension ; 63(4): 762-7, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24420549

RESUMO

Intranasal administration of angiotensin II (ANGII) affects blood pressure in a mode different from intravenously administered ANGII via a direct access to the brain bypassing the blood-brain barrier. This clinical study investigated blood pressure regulation after intranasal ANGII administration in healthy humans, whereas systemic, blood-mediated effects of ANGII were specifically blocked. In a balanced crossover design, men (n=8) and women (n=8) were intranasally administered ANGII (400 µg) or placebo after ANGII type 1 receptors had been blocked by pretreatment with valsartan (80 mg; 12 and 6 hours before intranasal administration). Plasma levels of ANGII, aldosterone, renin, vasopressin, and norepinephrine were measured; blood pressure and heart rate were recorded continuously. Intranasal ANGII acutely decreased blood pressure without altering the heart rate. Plasma levels of vasopressin and norepinephrine remained unaffected. Plasma ANGII levels were increased throughout the recording period. Aldosterone levels increased despite the peripheral ANGII type 1 receptor blockade, indicating an aldosterone escape phenomenon. In conclusion, intranasal ANGII reduces blood pressure in the presence of selective ANGII type 1 receptor blockade. Intranasal ANGII administration represents a useful approach for unraveling the role of this peptide in blood pressure regulation in humans.


Assuntos
Bloqueadores do Receptor Tipo 1 de Angiotensina II/farmacologia , Angiotensina II/administração & dosagem , Angiotensina II/farmacologia , Pressão Sanguínea/efeitos dos fármacos , Receptor Tipo 1 de Angiotensina/efeitos dos fármacos , Administração Intranasal , Adulto , Aldosterona/sangue , Pressão Sanguínea/fisiologia , Estudos Cross-Over , Método Duplo-Cego , Feminino , Frequência Cardíaca/efeitos dos fármacos , Frequência Cardíaca/fisiologia , Humanos , Hidrocortisona/sangue , Masculino , Sistema Renina-Angiotensina/efeitos dos fármacos , Sistema Renina-Angiotensina/fisiologia , Tetrazóis/farmacologia , Valina/análogos & derivados , Valina/farmacologia , Valsartana
7.
JAMA ; 307(10): 1046-52, 2012 Mar 14.
Artigo em Inglês | MEDLINE | ID: mdl-22416100

RESUMO

CONTEXT: An outbreak of Shiga toxin-producing enteroaggregative Escherichia coli (STEC O104:H4) infection with a high incidence of hemolytic uremic syndrome (HUS) occurred in Germany in May 2011. Antibiotic treatment of STEC infection is discouraged because it might increase the risk of HUS development. However, antibiotic therapy is widely used to treat enteroaggregative E coli infection. In the German outbreak, a substantial number of patients received prophylactic azithromycin treatment as part of a therapeutic regimen with the C5 antibody eculizumab. OBJECTIVE: To analyze the duration of bacterial shedding in patients with STEC infection who did and did not receive oral azithromycin therapy. DESIGN, SETTING, AND PATIENTS: At a single center in Lübeck, Germany, 65 patients with STEC infection, including patients with HUS as well as STEC-infected outpatients without manifestation of HUS, were investigated between May 15 and July 26, 2011, and were monitored for a mean of 39.3 days after onset of clinical symptoms. MAIN OUTCOME MEASURE: Carriage of STEC after azithromycin therapy. RESULTS: Twenty-two patients received oral azithromycin and 43 patients did not receive antibiotic treatment. Among antibiotic-treated patients, long-term STEC carriage (>28 days) was observed in 1 of 22 patients (4.5%; 95% CI, 0%-13.3%) compared with 35 of 43 patients (81.4%; 95% CI, 69.8%-93.0%) who were not treated with antibiotics (P < .001). All 22 patients receiving azithromycin treatment had at least 3 STEC-negative stool specimens after the completion of treatment, and no recurrence of STEC was observed in these patients. As proof of principle, 15 patients who initially were not treated with antibiotics and were long-term STEC carriers were treated with oral azithromycin given for 3 days and subsequently had negative stool specimens. CONCLUSION: Treatment with azithromycin was associated with a lower frequency of long-term STEC O104:H4 carriage.


Assuntos
Antibacterianos/administração & dosagem , Azitromicina/administração & dosagem , Derrame de Bactérias/efeitos dos fármacos , Infecções por Escherichia coli/tratamento farmacológico , Síndrome Hemolítico-Urêmica/tratamento farmacológico , Escherichia coli Shiga Toxigênica/patogenicidade , Adulto , Idoso , Portador Sadio/tratamento farmacológico , Surtos de Doenças , Infecções por Escherichia coli/epidemiologia , Infecções por Escherichia coli/microbiologia , Feminino , Alemanha/epidemiologia , Síndrome Hemolítico-Urêmica/epidemiologia , Síndrome Hemolítico-Urêmica/microbiologia , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Escherichia coli Shiga Toxigênica/isolamento & purificação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA